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Abstract
Background: The recognition of peptide in the context of MHC by T lymphocytes is a critical step in the initiation of an
adaptive immune response. However, the molecular nature of the interaction between peptide and MHC and how it
influences T cell responsiveness is not fully understood.
Results: We analyzed the immunological consequences of the interaction of MHC class II (I-A
u) restricted 11-mer peptides of
myelin basic protein with amino acid substitutions at position 4. These mutant peptides differ in MHC binding affinity, CD4
+
T cell priming, and alter the severity of peptide-induced experimental allergic encephalomyelitis. Using molecular dynamics,
a computational method of quantifying intrinsic movements of proteins at high resolution, we investigated conformational
changes in MHC upon peptide binding. We found that irrespective of peptide binding affinity, MHC deformation appears to
influence costimulation, which then leads to effective T cell priming and disease induction. Although this study compares in
vivo and molecular dynamics results for three altered peptide ligands, further investigation with similar complexes is
essential to determine whether spatial rearrangement of peptide-MHC and costimulatory complexes is an additional level of
T cell regulation.
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Introduction
A productive interaction between the peptide antigen (Ag) :
MHC class II complex on the surface of an Ag presenting cell
(APC) and the T cell receptor (TCR) on a CD4
+ T lymphocyte
leads to an immune response. However, the ability of peptide :
MHC class II (pMHC) to activate T cells depends upon many
factors including the stability of the complex, TCR : pMHC
interaction kinetics, the density of interacting TCRs, amongst
other factors [1]. In certain instances, altered peptide ligands
(APLs) derived by substituting key amino acids lead to dissociation
of effector T cell functions such as proliferation, cytokine
production, and disease induction or cause immune tolerance
[2,3] and might have potential therapeutic value for immune-
mediated diseases. An example of such an APL is the alanine
substitution at position 4 of the I-A
u restricted N-terminal 11-mer
peptide of myelin basic protein (MPB) (AcN1-11[4A]), which is a
poor immunogen that inhibits the induction of the MPB-specific
CD4
+ T cell-mediated experimental allergic encephalomyelitis
(EAE) model of multiple sclerosis in mice [4]. The native N-
terminal MBP peptide with a lysine at position 4, AcN1-11 is
characterized by a low binding activity [5], stimulates MBP-
specific T cell clones, primes for in vivo recall proliferative
responses, cytokine production, and induces EAE in H-2
u mice
[6,7]. However, a single amino acid substitution at position 4
changes the binding affinity of the peptide to I-A
u and alters MBP-
specific T cell responsiveness [8,9]. The binding affinity of AcN1-
9[4A] 9-mer to I-A
u (IC50 =0.019 mM) is higher than AcN1-9
(IC50 =7.4 mM), it stimulates MBP-specific T cell clones better
than the native peptide, but does not induce EAE and diminishes
the severity of EAE induced by the native peptide [4,8]. In
contrast, the methionine substitution, AcN1-9[4M], binds I-A
u
(IC50 =0.00064 mM) more avidly than AcN1-9 and is a good
immunogen [4,8,9], illustrating that binding affinity with MHC
class II may not correlate with immune responsiveness and
suggests that additional mechanisms may be involved.
The intrinsic motions of proteins, determined by covalent and
non-covalent forces, cause conformational changes with intermo-
lecular and intercellular ramifications on signaling pathways, cell
function, and physiological responses. Molecular dynamics (MD) is
a computational approach used to examine conformational
dynamics of molecules at high resolution in space and time [10].
Because the binding affinities of APLs to MHC do not accurately
predict in vivo immunogenicity, we sought to evaluate peptide and
MHC interaction dynamics and correlate these movements and
conformational changes with functional immunological conse-
quences. Since it has already been shown that conformational
differences between peptide : MHC complexes can explain the
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phenomena [12] or the recognition of MHC class II binding
epitopes [13], we suggest that the spatial dynamics of MD can
further reveal aspects of T cell activation.
Materials and Methods
Mice
Female (PL/J 6SJL) F1 mice (6–8 weeks old) were purchased
from Jackson laboratories (Bar Harbor, ME) or were bred at the
Yale University animal facility (New Haven, CT). The animal
experiments were conducted at Yale University and passed the
‘‘Yale University Institutional Animal Care and Use Committee’’
(IACUC). All animal studies were performed in accordance with
the guidelines of the IACUC.
Antibodies
The mAbs were purified from the hybridoma supernatants
maintained in the lab. The following mAbs used in this study: GK
1.5 (rat IgG2b, anti-CD4), TIB105 (rat IgG2a, anti-CD8 clone
53–6.72), Y3JP (mouse IgG2, anti-I-A
u), Y19 (anti-Thy 1), 14.4.4s
(mouse IgG2a, anti-I-E), 37.51 (hamster IgG, anti-CD28) obtained
from Pharmingen (San Diego, CA) or 37.51 ascites kindly
provided by J. Allison (Sloan-Kettering, NY).
Preparation of MBP Peptides
Peptides were synthesized using a solid-phase peptide synthe-
sizer (430A; Applied Biosytems, Inc., Foster City, CA), purified
and characterized by high pressure liquid chromatography
(HPLC) and mass spectrophotometry. Each peptide ran as a
single peak on HPLC and had the predicted amino acid content
and molecular weight by mass spectrophotometry. Peptide
sequences are: AcN1-11:ASQKRPSQRHG; AcN1-11[4A]:AS-
QARPSQRHG; AcN1-11[4M]:ASQMRPSQRHG. The Ac de-
notes N-terminal acetylation.
T cell clones and lines
The CD4
+ T clone 19 kindly provided by C. A. Janeway (Yale
University) was maintained by stimulation with 6610
6 irradiated
(2700 rad) syngeneic spleen cells per T-75 flask, plus AcN1-11
(5 mg/ml), and 5 U/ml recombinant murine IL-2 (rIL-2) (Boeh-
ringer Mannheim Corporation, Indianapolis, IN).
MBP peptide induced EAE
We injected each peptide (200 mg) dissolved in PBS and
emulsified in Complete Freund’s Adjuvant (CFA) containing
4 mg/ml Mycobacterium tuberculosis H37RA (Difco Laboratories
Inc., Detroit, MI) subcutaneously in the flanks (100 mg each flank)
on day 0 followed by two intravenous doses of 200 ng Bordetella
pertussis toxin given on days 0 and 2 (List Biologicals, CA). We
observed animals daily and graded for clinical disease in a blinded
fashion. Mean maximum severity scores for EAE were done using
the following grading criteria: Grade 1. limp tail; grade 2. limp tail
and weak hind limbs; Grade 3. hind limb paralysis; Grade 4. fore
limb paralysis; Grade 5. moribund; Grade 6. death. To test the
effect of anti-CD28 on disease induction, we injected mAb
(100 mg/100 ml) intraperitoneal (i.p.) on days 1, 3, 5, 7 and 9.
Proliferation assays
MBP peptides (200 mg) were dissolved in PBS and emulsified
with an equal volume of CFA containing 4 mg/ml Mycobacterium
tuberculosis H37RA. For testing the effect of in vivo anti-CD28, we
injected purified anti-CD28 (100 mg/100 ml) i.p. at the time of
immunization and at day 3, 5 and 7. Ten days after the animals
were immunized subcutaneously (50 mg/site) at the tail base,
draining inguinal and paraaortic lymph nodes were removed. We
purified CD4
+ T cells using immunomagnetic negative selection in
which the lymph node cells were incubated with anti-CD8 (TIB
105), anti-H-2
u (Y3JP) antibodies in Hanks buffered salt solution
(HBSS) at 4uC for 1 h, followed by incubation with goat anti-
mouse and goat anti-rat IgG magnetic beads (Collaborative
Research Incorporated, Bedford, MA) at 4uC for 1 h. Magnetic
selection yielded 95–97% pure CD4
+ T cells analyzed by flow
cytometry. APCs were prepared by incubating splenocytes from
non-immunized mice with anti-CD8 (TIB 105), anti-CD4 (GK
1.5) and anti-Thy 1 (Y19) for 1 h at 4uC, following the removal of
erythrocytes by density gradient centrifugation with lymphocyte
separation media. We then incubated antibody coated cells with
rabbit complement at 37uC for 30 min causing complement-
mediated killing, yielding 92–95% pure MHC class II bearing cells
demonstrated by FACS analysis.
For proliferation assays, mitomycin C-treated APCs (2610
5) per
well and CD4
+ T cells (2610
5) or clone 19 cells (1610
5) in a total
100 ml of Eagles high amino acid media (EHAA) supplemented
with 5% FCS, 50 U/ml penicillin, 50 mg/ml streptomycin sulfate,
and 10 mM Hepes were plated in triplicate on a 96-flat bottom
well microtitre plate (Costar, Cambridge, MA) with peptide or
media alone for 5 days at 37uC, 5% CO2, and humidified air. rIL-
2 or anti-CD28 ascites or isotype-matched control ascites were
added to secondary cultures at the time of the initial setup to
maintain a total of 100 ml/well for in vitro assay. We added 1 mCi
[
3H]-thymidine (6.7 Ci/mmol, ICN Biomedicals Inc., Irvine, CA)
per well at 96 h and harvested 18–24 h later. Results are
presented as averages of triplicates and standard errors were
,20% unless otherwise indicated.
Cytokine Assays
Bioassays for IFNc were done by standard protocols, in which we
incubated 40 ml of culture supernatant with 20 ml (5000 cells/well) of
WEHI-279 indicator cells (ATCC, Rockville, MD) in the presence
and absence of anti-IFNc to measure IFNc and pulsed cultures with
[
3H]-thymidine at 24 h and harvested 24 h after. One unit of IFNc is
the concentration, which gave half maximal inhibition of WEHI-279
proliferation calculated from the standard curve obtained with a
murine rIFNc standard (Genzyme Corp., Boston, MA). In all assays,
anti-IFNc blocked inhibition.
Molecular dynamics
MD studies started with the crystallographic pMHC structure
(pdb-id 1k2d [14]), containing a peptide which is most similar to
our target MBP AcN1-11 : I-A
u (compared to pdb-id 2p24 and
pdb-id 1u3h containing less related peptides and pdb-id 2pxy
containing TCR fragments making all these less optimal choices).
Therefore, using pdb-id 1k2d, we could model MBP AcN1-11,
AcN1-11[4A], and AcN1-11[4M] peptides into the binding groove
of the MHC molecule in only 4 steps, 1.) removed the four N-
terminal residues whose backbones are unnecessary for the
modeling process, 2.) attached the missing three C-terminal
residues using SPDBV [15], 3.) modeled an acetyl-group N-
terminally to the peptide, and 4.) mutated the tyrosine at position 4
to lysine, alanine, and methionine using the SCWRL software
[16]. Subsequently, MD simulations are carried out using
Gromacs [17]; We immersed each modeled structure into a 3D
water cube of 127 A ˚ side length allowing for a minimum distance
of 20 A ˚ between protein and box-boundary [18] and applied
periodic boundary conditions. Subsequently, we minimized each
system energetically using a steepest descent method and then
MD of pMHC Binding
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for a simulation time corresponding to approximately 22 ns of real
time for each system. We used Gromacs to analyse the simulations
and resulting trajectories [17]. We used built-in analyses tools of
Gromacs for root mean square deviation (RMSD) evaluations.
Results
AcN1-11 induces dramatic changes in the a-helical
conformation of residues 65–69 of the MHC a1-chain
(r65-69a)
To evaluate the effects of peptide binding on MHC class II
structure, we used the in silico MD method to calculate spatial
changes of the side-chain of the native AcN1-11 peptide in MHC
pocket 6 (Fig. 1a and 1c). The most similar experimental I-A
u
crystal structure available contains the AcN1-11[4Y] peptide with
a tyrosine occupying position 4 [14]. Upon in silico substitution of
native peptide for AcN1-11[4Y] at the start of MD, we observed
that within the first nanosecond (ns) of simulation, AcN1-11 leaves
MHC pocket 6 and interacts with the lateral a-helix of the MHC
a-chain (Fig. 1b and 1d). Thereby, inducing a distortion of a span
of 5 residues (65-69a) in the a -helix of the MHC, causing a
widening of the peptide binding groove without affecting the
overall structure of the peptide backbone (Fig. 1b and 1d).
To quantify the deformation of the 65–69 amino acid span of
the MHC a1-helix, which directly neighbors position 4 of the
peptide, we calculated the running average RMSD of this region,
separately for each peptide (Fig. 1e). To focus on (internal
deformations of) the a1-helix conformation, excluding the overall
movement of the structure, we fitted the simulation trajectory to
the neighboring 10 residues (5 on each side) in the a1-helix and
calculated RMSDs. These data confirm that AcN1-11 causes the
largest deformation of the r65-69a span of the a-helical structure
compared to the other peptides (Fig. 1e). This is also illustrated in
the rendered images Fig. 1b and 1d, where AcN1-11 disrupts the
a1-helix at G67, which is the center of deformation of the MHC
and affects the neighboring A65, T66, K68, and H69 residues as
well. We used Visual Molecular Dynamics (VMD, [19]) to
illustrate the behavior of lysine at position 4 in a sequence of
rendered images during the 22 ns of movement of the peptide
within MHC pocket 6 (Movie S1). The average RMSD value over
the entire simulation period was 0.404 nm for AcN1-11, whereas
AcN1-11[4A] and AcN1-11[4M] averaged only 0.185 nm, and
0.156 nm, respectively. These data demonstrate that AcN1-11
induces a spatial rearrangement in the MHC a1-helix that alters
the r65-69a span so that it does not conform with the definition of
an a-helical structure [20] (Fig. 1b).
AcN1-11 and AcN1-11[4M] but not AcN1-11[4A] deform
the MHC
RMSD evaluations pertaining to the entire a1- and a2- helices
show a different picture. AcN1-11[4M] deformed the overall
spatial arrangement of the a1- and a2- helices and AcN1-11[4A]
caused almost no deformation (Fig. 2A). The average RMSD
value for AcN1-11[4A] is 0.295 nm, whereas AcN1-11 and AcN1-
11[4M] are similar at 0.459 nm and 0.469 nm, respectively.
Interestingly, the RMSDs for AcN1-11 and AcN1-11[4M] are
similar despite the fact that AcN1-11 only deforms a small span
(r65-69a), whereas AcN1-11[4M] causes overall deformation of
the helices by influencing almost all of the residues of the MHC
a1-helix. These data show that AcN1-11[4M] and AcN1-11
induce structural changes to the entire MHC class II molecule not
observed with AcN1-11[4A]. This picture is accentuated when
evaluating the entire MHC structure, including the b-chain. We
observed that AcN1-11[4M] not only induced changes in the a1-
helix but also affected the a2-helix of the MHC b-chain (Fig. 2b),
leading to a higher average RMSD of 0.362 nm compared to
AcN1-11 and AcN1-11[4A], which average 0.248 nm and
0.246 nm, respectively. Additionally, AcN1-11[4M] is the only
peptide capable of deforming the b-sheet floor below position 4 of
the peptide (4
th strand of the b-sheet, r185–190 of the b-chain)
(Fig. 2c), with average RMSDs for AcN1-11[4M] of 0.367 nm,
AcN1-11 of 0.233 nm, and AcN1-11[4A] of 0.211 nm. These data
show that both AcN1-11[4M] and AcN1-11 differ from AcN1-
11[4A] by deforming the a1-helix, and that AcN1-11[4M] differs
from AcN1-11[4A] and AcN1-11 by deforming both the a2-helix
and b-sheet.
Structural rearrangements and experimental binding
affinities
Unlike the binding of AcN1-11 to MHC, where the side-chain
of lysine at position 4 immediately leaves MHC pocket 6, the side-
chains at position 4 of AcN1-11[4A] and AcN1-11[4M] stay inside
MHC pocket 6 for the whole simulation time. The side-chain of
AcN1-11[4M] wedges into pocket 6 forming an anchor (Fig. 2d),
whereas the side-chain of AcN1-11[4A] is too small to be an
anchor. These data predict that AcN1-11[4A] and AcN1-11[4M]
would have higher binding affinity than the native peptide to
MHC and that the anchoring of AcN1-11[4M] would further
increase binding affinity, which agrees with measured binding
affinities. Despite the lack of position 4 side-chain anchoring of
AcN1-11[4A] and avid binding, there is almost no conformational
change induced in the MHC, which results in increased MHC
stability.
AcN1-11 and AcN1-11[4M] but not AcN1-11[4A] induce
EAE
To compare MD simulations with in vivo immunogenicity, we
primed H-2
u mice with each MBP peptide and adjuvant and
observed mice for disease one week after immunization. Table 1
shows that AcN-1-11[4A] does not induce disease, but the native
peptide and the AcN-1-11[4M] peptide could generate EAE.
Moreover, AcN-1-11[4M] induced more severe disease in 100%
of mice compared to disease induction in 80% of mice immunized
with the native peptide.
AcN1-11 and AcN1-11[4M] prime for proliferation and
cytokines but AcN1-11[4A] primes only for IFNc
production
To further characterize in vivo peptide responses, we immunized
mice with individual peptides and cultured purified CD4
+ T cells
from draining lymph nodes with all peptides in the presence of
APCs. All three peptides are capable of re-stimulating MBP-
specific CD4
+ T cell line, clone 19 with AcN1-11[4A] and AcN1-
11[4M] inducing higher proliferative responses than the native
peptide (Fig. 3a). However, when the peptides are used to
stimulate in vitro secondary responses from peptide-primed CD4
+
T cells, primed AcN1-11[4A] cells are unable to mount a
proliferative recall response to any of the peptides suggesting that
in vivo priming did not occur (Fig. 3b). In contrast, AcN1-11 and
AcN1-11[4M] primed CD4
+ T cells, like Clone 19, respond to
AcN1-11[4M] better than AcN1-11 and AcN1-11[4A]. To rule
out that the kinetics of priming and dose of peptide were not
responsible for the lack of in vivo priming by AcN1-11[4A], we
tested AcN1-11[4A] primed CD4
+ T cells after repeated
immunizations and a range of doses from 0.0005 mg to 500 mg
and found no response in recall to MBP peptides despite a normal
MD of pMHC Binding
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protein derivative (data not shown). Although AcN1-11[4A]
immunized mice generated CD4
+ T cells unable to proliferate
upon secondary Ag rechallenge, it was possible that the cells
generated were effector cells able to produce cytokines. To test this
possibility, we stimulated each peptide-immunized CD4
+ T cell
population with a secondary in vitro challenge of the immunizing
peptide and found that AcN1-11[4A]-primed CD4
+ T cells
produced IFNc and that the amount secreted followed the
binding affinity with IFNc levels; AcN1-11[4M] . AcN1-11[4A]
Figure 1. Deformation of r65-69a of the MHC. (a) Top view onto the modeled MBP AcN1-11 : I-A
u complex. The MHC a-chain (blue), and the
MHC b-chain (red) are represented as a cartoon. The peptide (yellow), represented in licorice style, is bound to the MHC at the peptide binding
groove. The lysine at position 4 (orange) is buried in MHC pocket 6. (b) Average structure during simulation from time t=15 ns to t=22 ns. The lysine
at position 4 left the groove and is bound to the lateral helix of the MHC a-chain, causing a disruption of the helical structure next to position 4 and a
widening of the groove at the N-terminal half (i.e. the left side of the picture). (c) Thin cross-section through the MHC pocket 6 of the modeled
complex. (d) Same as C but for the average structure during simulation from time t=15 ns to t=22 ns. (e) Moving average RMSD of residues 65–69 of
the a1-helix of the MHC. Ac1-11 causes the largest deformation in this area of the a1-helix compared to Ac1-11[4A] and Ac1-11[4M]. The moving
average is calculated using the neighboring 1000 frames (500 on the left and 500 on the right).
doi:10.1371/journal.pone.0011653.g001
MD of pMHC Binding
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+ T cells produced IFNc when cell
populations were incubated with medium alone (data not shown).
Taken together, these data illustrate the peculiar behavior of
AcN1-11[4A] primed CD4
+ T cells. AcN1-11[4A] neither primes
for secondary in vitro proliferation or in vivo disease, but primes for
Ag-specific IFNc production. This suggests that the alanine
substituted peptide causes partial CD4
+ T cell priming.
Anti-CD28 restores AcN1-11[4A] proliferation
Because AcN1-11[4A] could prime for cytokine production but
not for T cell proliferation, we hypothesized that priming for
proliferation and cytokine production vs. cytokine production
alone may be related to insufficient costimulatory signals (via
CD28) and/or growth factors, such as IL-2, which is a growth
factor crucial for T cell proliferation. We tested this hypothesis by
adding either anti-CD28 or rIL-2 to in vitro cultures to test whether
we could reconstitute effective T cell priming. We added titrated
doses of rIL-2 or anti-CD28 in vitro to AcN1-11[4A] primed CD4
+
T cells and recall peptide. We found that both rIL-2 and anti-
CD28 restored proliferation if the mice were primed with AcN1-
11[4A] (Fig. 3d). Mice immunized with PBS/CFA alone (without
peptide) were unable to proliferate in the presence of peptide, rIL-
2 or anti-CD28 (data not shown).
Since costimulation reconstituted proliferation of partially
primed AcN1-11[4A]-specific CD4
+ T cells in vitro, we tested the
effect of the addition of costimulation upon initial in vivo priming.
We observed that i.p. injections with anti-CD28 (clone 37.51)
following priming with AcN1-11[4A] proliferated to AcN1-11[4A]
Figure 2. Structural rearrangements of the MHC. (a) Deformation of the a1-helix of the MHC. The average RMSD of AcN1-11 and AcN1-11[4M]
are similar although the RMSD for AcN1-11 primarily results form deformation of residues 65 to 69, while AcN1-11[4M] deforms the whole helix. (b)
Deformation of the a2-helix of the MHC. Only Ac1-11N[4M] affects the structure of the a2-helix. (c) Deformation of the ß-sheet floor below position 4
of the peptide. AcN1-11[4M] deforms the floor at a much higher level than the other two derivates. (d) 3D representation of the complex. The
methionine side-chain stays in pocket 6 over the whole simulation time. The a1-helix is hidden to improve visualization of the binding groove. White:
MHC. Yellow: peptide. Orange: Ac1-11[4M].
doi:10.1371/journal.pone.0011653.g002
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only could anti-CD28 and the addition of rIL-2 in vitro reconstitute
proliferation, but it was also possible to restore recall proliferation
during the priming event. We then proceeded to test the possibility
that the addition of anti-CD28 in vivo during disease induction
would induce EAE. Several doses of anti-CD28 were injected
following AcN1-11[4A] priming, but EAE could not be generated
(data not shown). While AcN1-11[4A] CD4
+ T cells are able to
proliferate in response to AcN1-11[4A] ex-vivo, additional factors
may be necessary for these cells to track to the central nervous
system (CNS) and induce disease and the dose of costimulation
may not be high enough to effectively induce pathogenic
lymphocytes.
Discussion
Here, we present an approach to elucidate potential mecha-
nisms underlying molecular interactions that explain crucial
immunological phenomena by combining experimental and
computational data. MD have shed insights on the intrinsic
dynamic properties of proteins by illustrating that binding events
influence molecular, cellular, and intercellular interactions and
that these effects direct signaling networks [21]. It allows
measurements of protein movements in angstrom distances
providing new information about intermolecular interactions,
which potentially relate to in vivo functional outcomes.
Figure 3. MBP-specific CD4
+ T cell responses to native and altered peptide ligands. (a) MBP-specific clone 19 cells were incubated with
splenic APCs and peptides or media alone for 96 h. Proliferation was measured 18 h after
3[H]-thymidine was added to cultures. (b) CD4
+ T cells from
mice immunized with either AcN1-11, AcN1-11[4A] or AcN1-11[4M] were incubated with peptides and splenic APCs. Proliferation was measured 18 h
after
3[H]-thymidine was added to cultures. (c) Supernatants (96-h) from AcN1-11, AcN1-11[4A], and AcN1-11[4M]-primed CD4
+ T cells cultured with
AcN1-11, AcN1-11[4A], AcN1-11[4M] or media alone, and splenic APCs were tested for IFNc by bioassay. (d) AcN1-11[4A] primed CD4
+ T cells were
cultured for 96 h in the presence of 100 or 50 Units/ml rIL-2, anti-CD28 ascites (1:2000 dilution) or media and splenic APCs. Proliferation was
measured 18 h after
3[H]-thymidine was added to cultures. (e) CD4
+ T cells from mice immunized with AcN1-11[4A] followed by i.p. anti-CD28 or PBS
were incubated with splenic APCs, AcN1-11[4A] or media alone. Proliferation was measured 18 h after
3[H]-thymidine was added to cultures. These
data are mean 6 SEM. n=5 mice per group, with a minimum of 3 experimental repetitions.
doi:10.1371/journal.pone.0011653.g003







AcN1-11[4A] 0 0 0
AcN1-11 80 13 3.4
AcN1-11[4M] 100 14 4.0
*n=10 mice/group, 4 experiments.
doi:10.1371/journal.pone.0011653.t001
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of three peptides within the MHC groove and the consequent
conformational changes of MHC, which appears to influence
costimulation, T cell activation, and EAE induction. These and
other MD simulations provide a potentially new mechanism
underlying why peptide affinity to MHC alone does not sufficiently
explain the exceptional behavior of APLs like AcN1-11[4A]. Our
data suggest that in vivo effects correlate with spatial rearrangements
between peptide and MHC. These data illustrate on a subset of well-
studied peptides that MD simulations could provide interesting
insights into the relationship between spatial dynamics of pMHC
interactions and immunological outcomes.
Further investigations using MD simulations will be critical for
determining whether this approachoccurs only with certain classes of
peptide or is a broader phenomenon. It is necessary to study a whole
range of pMHC interactions, comparing MD simulations with in vivo
data to determine the generalizability of molecular mechanisms
through which conformational changes in MHC molecules are
translated into alterations in T cell proliferation and function.
Nevertheless, well-tailored MD simulations that correlate with
functional immunological outcomes [22,23,24,25,26,27,28,29] may
be useful for designing therapeutic APLs to treat diseases such as
multiple sclerosis [30,31,32].
Supporting Information
Movie S1 Movie illustrating the loss of helical structure. The
side-chain of AcN1-11 (orange) of the peptide backbone (yellow)
disrupts the alpha -helix at r65-69alpha span (green) of the helical
structure of the alpha-chain of MHC (blue). beta-chain is depicted
in red.
Found at: doi:10.1371/journal.pone.0011653.s001 (3.70 MB
MOV)
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